Revvity Partners with Eli Lilly to Launch AI Drug Discovery Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 13h ago
0mins
Source: NASDAQ.COM
- Collaborative Innovation: Revvity's partnership with Eli Lilly integrates Lilly's AI-driven predictive modeling platform, Lilly TuneLab, into the Revvity Signals platform, aiming to expand access to advanced AI tools for drug discovery and enhance research efficiency.
- Data Security Assurance: The collaboration establishes a scalable federated framework that allows biotech companies to apply Lilly's predictive models to their research programs while keeping proprietary data private and secure, ensuring both data confidentiality and research flexibility.
- Funding Support Initiative: Revvity and Lilly will jointly fund access for selected participants, including the use of Signals One and Signals Xynthetica software along with modeling credits, aiming to lower barriers to AI adoption across the biotech sector and promote technology proliferation.
- Integration Advantage: Lilly TuneLab offers AI and machine learning models trained on decades of Lilly research data, enhanced through federated learning, while Revvity's Signals platform integrates these models into existing scientific workflows, significantly boosting overall drug discovery efficiency.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1078 USD with a low forecast of 800.00 USD and a high forecast of 1300 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1085.190
Low
800.00
Averages
1078
High
1300
Current: 1085.190
Low
800.00
Averages
1078
High
1300
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
